Radiotherapy For Gynecologic Malignancies Research Articles

Quality Assurance for Stereotactic Body Radiation Therapy for Gynecologic Malignancies.

The use of stereotactic body radiation therapy (SBRT) is not well studied or reported in the treatment of gynecologic malignancies, despite its success in the definitive management of other cancer sites. This report describes a rigorous quality assurance process for patients to undergo dose escalation to the pelvis via stereotactic photon beam irradiation. Patients who receive SBRT must be ineligible for conventional brachytherapy boost and undergo comprehensive informed consent. Fiducial placement, bowel prep, Foley catheter placement with standardized bladder filling, computerized tomography (CT) simulation with whole-body immobilization, magnetic resonance imaging (MRI)-assisted target delineation, planning aims based on the established brachytherapy literature, and physics consultation for SBRT plan optimization are necessary. Prior to each fraction, the simulation position is reproduced and verified with on-table cone beam CT, and the position is maintained with whole-body immobilization. Following treatment, the treating physician is active in survivorship and toxicity management. Gynecologic SBRT is an ongoing area of study, and preliminary successes in delivering high-quality stereotactic dose escalation suggest prospective investigation is warranted. By adhering to strict quality control measures and following a pre-defined best standard of practice, patients with gynecologic malignancies who are ineligible for traditional brachytherapy procedures can be safely treated with SBRT.

Sleep Disorders Prior to Adjuvant Radiation Therapy for Gynecological Malignancies.

Many patients with gynecological malignancies receive postoperative radiotherapy, which can lead to fear and sleep disorders. We aimed to identify the prevalence of and risk factors for sleep disorders. Sixty-two patients assigned to radiotherapy for gynecological malignancies were retrospectively evaluated. Seventeen characteristics were analyzed for associations with pre-radiotherapy sleep disorders including age, Karnofsky performance score, Charlson comorbidity index, history of additional malignancy, family history of gynecological cancer, distress score, emotional, physical or practical problems, tumor site/stage; chemotherapy, treatment volume, brachytherapy, and the COVID-19 pandemic. The prevalence of pre-radiotherapy sleep disorders was 46.8%. Sleep disorders were significantly associated with Charlson comorbidity index ≥3 (p=0.012), greater number of physical problems (p<0.0001), and advanced primary tumor stage (p=0.005). A trend was found for greater number of emotional problems (p=0.075). Pre-radiotherapy sleep disorders are common in patients with gynecological malignancies, particularly in those with specific risk factors. Patients should be offered early psychological support.

Impact of diabetes on gastrointestinal and urinary toxicity after radiotherapy for gynecologic malignancy.

Objective:Although diabetes is a common co-morbidity in patients with gynecologic cancer, information about its impact on radiation toxicity in patients with gynecologic cancer treated with external pelvic irradiation is scarce. We aimed to investigate the relation of diabetes with acute toxicity in patients with gynecologic tumors who underwent pelvic +/- paraaortic radiotherapy.Materials and Methods:One hundred twenty-nine patients with endometrium or cervix carcinoma were enrolled in the study. Demographic features, presence of diabetes, incidence and severity of upper gastrointestinal (UGIS), lower gastrointestinal (LGIS), and urinary symptoms were recorded from files. Correlation and logistic regression analysis was used to determine the impact of diabetes, age, chemotherapy, paraaortic irradiation on toxicities, and a prediction model was developed.Results:The median age of 77 patients with endometrium cancer and 52 cervix cancer was 61 (range, 25-92) years, and 28 (21.7%) of them had diabetes. The median pelvic and tumor/tumor bed dose was 5040+247.65 cGy and 5040+222.91 cGy, respectively. Age and Gr 0 UGIS toxicity were significantly related (p=0.047). LGIS Gr 0 toxicity was found to be significantly higher in patients with diabetes (p=0.045). Gr 0 and 2 UGIS toxicities were both found to be significantly correlated with paraaortic irradiation (both p<0.001). Diabetes is also an important determinant on UGIS toxicity in patients who underwent paraaortic irradiation.Conclusion:The correlation we found between toxicity and diabetes, concurrent chemotherapy or paraaortic radiation necessitates special care and risk stratification for patients with diabetes. Further prospective studies with long follow-up and larger patient groups are warranted.

COVID-19, Brachytherapy, and Gynecologic Cancers: a Moroccan Experience.

The treatment of gynecological cancers is the main activity of brachytherapy units. However, during COVID-19 pandemic, precautions should be done in order to reduce the spread of the virus while maintaining all chances to recovery for all patients (Radiother Oncol 148, 227-228, 2020). Despite the extent of the pandemic in our country, limited data are available to establish recommendations with a sufficient level of evidence (Radiother Oncol 148, 227-228, 2020). More recently, the American Brachytherapy Society published some clarifications in this regard and international expert consensus recommendations of radiation therapy for gynecologic malignancies during the COVID-19 pandemic were published (https://www.americanbrachytherapy.org/about-abs/abs-news/abs-statement-on-coronavirus/, Gynecol Oncol 15, 2020). In this commentary, we sought to share the procedures adopted for the management of gynecological cancer patients during COVID-19 pandemic in our brachytherapy unit.

Radiation therapy for gynecologic malignancies during the COVID-19 pandemic: International expert consensus recommendations

ObjectiveTo develop expert consensus recommendations regarding radiation therapy for gynecologic malignancies during the COVID-19 pandemic. MethodsAn international committee of ten experts in gynecologic radiation oncology convened to provide consensus recommendations for patients with gynecologic malignancies referred for radiation therapy. Treatment priority groups were established. A review of the relevant literature was performed and different clinical scenarios were categorized into three priority groups. For each stage and clinical scenario in cervical, endometrial, vulvar, vaginal and ovarian cancer, specific recommendations regarding dose, technique, and timing were provided by the panel. ResultsExpert review and discussion generated consensus recommendations to guide radiation oncologists treating gynecologic malignancies during the COVID-19 pandemic. Priority scales for cervical, endometrial, vulvar, vaginal, and ovarian cancers are presented. Both radical and palliative treatments are discussed. Management of COVID-19 positive patients is considered. Hypofractionated radiation therapy should be used when feasible and recommendations regarding radiation dose, timing, and technique have been provided for external beam and brachytherapy treatments. Concurrent chemotherapy may be limited in some countries, and consideration of radiation alone is recommended. ConclusionsThe expert consensus recommendations provide guidance for delivering radiation therapy during the COVID-19 pandemic. Specific recommendations have been provided for common clinical scenarios encountered in gynecologic radiation oncology with a focus on strategies to reduce patient and staff exposure to COVID-19.

Impact of Diabetes on Gastrointestinal and Urinary Toxicity after Radiotherapy for Gynecologic Malignancy

Impact of Diabetes on Gastrointestinal and Urinary Toxicity after Radiotherapy for Gynecologic Malignancy

Proton Therapy Reduces Normal Tissue Dose Compared to Intensity Modulated Radiation Therapy in Extended Field Pelvic Radiation Therapy for Gynecologic Malignancies

Proton Therapy Reduces Normal Tissue Dose Compared to Intensity Modulated Radiation Therapy in Extended Field Pelvic Radiation Therapy for Gynecologic Malignancies

NTCP modeling analysis of acute hematologic toxicity in whole pelvic radiation therapy for gynecologic malignancies – A dosimetric comparison of IMRT and spot-scanning proton therapy (SSPT)

PurposeThis treatment planning study was conducted to determine whether spot scanning proton beam therapy (SSPT) reduces the risk of grade ⩾3 hematologic toxicity (HT3+) compared with intensity modulated radiation therapy (IMRT) for postoperative whole pelvic radiation therapy (WPRT). Methods and materialsThe normal tissue complication probability (NTCP) of the risk of HT3+ was used as an in silico surrogate marker in this analysis. IMRT and SSPT plans were created for 13 gynecologic malignancy patients who had received hysterectomies. The IMRT plans were generated using the 7-fields step and shoot technique. The SSPT plans were generated using anterior-posterior field with single field optimization. Using the relative biological effectives (RBE) value of 1.0 for IMRT and 1.1 for SSPT, the prescribed dose was 45Gy(RBE) in 1.8Gy(RBE) per fractions for 95% of the planning target volume (PTV). The homogeneity index (HI) and the conformity index (CI) of the PTV were also compared. ResultsThe bone marrow (BM) and femoral head doses using SSPT were significantly lower than with IMRT. The NTCP modeling analysis showed that the risk of HT3+ using SSPT was significantly lower than with IMRT (NTCP=0.04±0.01 and 0.19±0.03, p=0.0002, respectively). There were no significant differences in the CI and HI of the PTV between IMRT and SSPT (CI=0.97±0.01 and 0.96±0.02, p=0.3177, and HI=1.24±0.11 and 1.27±0.05, p=0.8473, respectively). ConclusionThe SSPT achieves significant reductions in the dose to BM without compromising target coverage, compared with IMRT. The NTCP value for HT3+ in SSPT was significantly lower than in IMRT.

Incontinence, Voiding Dysfunction, and Other Urologic Complications After Radiotherapy for Gynecologic Malignancies

Women with newly diagnosed gynecologic cancer will undergo treatment with surgery, radiation, or combination therapy. A considerable proportion of these women will develop urologic complications including urinary incontinence, urinary retention, radiation cystitis, ureteral stricture, or genitourinary fistula. Diagnosis is typically made with a careful history, physical exam, endoscopy, urodynamics, and imaging. Non-surgical and surgical management of urologic complications following radiotherapy is complicated by local tissue damage resulting in inferior success rates when compared to the general population. It is imperative that the patient and physician understand the complexity of treatment and manage expectations accordingly.

The association of the uterine motion with bladder volume during radiotherapy in gynecological malignancies

The Journal of Cancer Metastasis and Treatment is an open access journal focused on cancer metastasis and treatment, including the occurrence, development, progression, metastasis, and treatment of oncologic disease. It covers basic, translational and clinical research related to cancer cell biology, genomics, precision medicine, oncology internal medicine, radiotherapy and radiology, obstetrics and gynecology, pediatrics, surgery, hematology, neurooncology, etc.

EP-1670: Impact of flatting filter free photon beam on Rapid-arc radiotherapy for gynecological malignancies

EP-1670: Impact of flatting filter free photon beam on Rapid-arc radiotherapy for gynecological malignancies

Rectal Balloon Use Limits Vaginal Displacement in Radiation Therapy for Gynecological Malignancies

Rectal Balloon Use Limits Vaginal Displacement in Radiation Therapy for Gynecological Malignancies

NTCP Modeling Analysis of Acute Hematologic Toxicity in Whole-Pelvic Radiation Therapy for Gynecologic Malignancies: A Dosimetric Comparison of IMRT and Spot-Scanning Proton Therapy

NTCP Modeling Analysis of Acute Hematologic Toxicity in Whole-Pelvic Radiation Therapy for Gynecologic Malignancies: A Dosimetric Comparison of IMRT and Spot-Scanning Proton Therapy

Psychosocial encounters correlates with higher patient-reported functional quality of life in gynecological cancer patients receiving radiotherapy.

BackgroundOur objective was to assess longitudinal health-related quality of life (HRQoL) in patients treated with radiotherapy for gynecologic malignancy and assess the relationship of psychosocial encounters on HRQoL.MethodsWomen with gynecologic malignancy were prospectively enrolled and HRQoL assessed before, during, and after radiotherapy treatment using validated measures. Treatment and demographic information were reviewed. Mixed-effects models were used to assess changes in quality of life (QoL) over time and association of psychologist and social worker encounters with overall QoL as well as subdomains of QoL.ResultsFifty-two women were enrolled and 41 completed at least one assessment. Fatigue (p = 0.008), nausea (p = 0.001), feeling ill (p = 0.007), and being bothered by side effects (p < 0.001) worsened on treatment with subsequent improvement. By follow-up, patients reported increased functional well-being (FWB) with significant decrease in worry (p = 0.003), increase in enjoyment of things usually done for fun (p = 0.003) and increase in contentment (p = 0.047). Twenty-three patients had at least one interaction with a social worker or psychologist during treatment. Each additional interaction was associated with a 2.12 increase in FWB score from before to after treatment (p = 0.002), and 1.74 increase from on to after treatment (p = 0.011). Additional interactions were not significantly associated with changes in overall FACT score (p = 0.056) or SWB (p = 0.305).ConclusionsPatient-reported HRQoL significantly worsened during radiotherapy treatment with subsequent improvement, affirming transiency of treatment-induced toxicities. Our preliminary study suggests that clinically-recommended psychological and social work interventions have potential value with respect to improving patient QoL during radiotherapy. Larger studies are needed to validate our findings.

Stereotactic Ablative Radiation Therapy for Gynecological Malignancies in the Oligometastatic Setting

Stereotactic Ablative Radiation Therapy for Gynecological Malignancies in the Oligometastatic Setting

3D Ultrasound Nakagami Imaging for Radiation-Induced Vaginal Fibrosis.

Radiation-induced vaginal fibrosis is a debilitating side-effect affecting up to 80% of women receiving radiotherapy for their gynecological (GYN) malignancies. Despite the significant incidence and severity, little research has been conducted to identify the pathophysiologic changes of vaginal toxicity. In a previous study, we have demonstrated that ultrasound Nakagami shape and PDF parameters can be used to quantify radiation-induced vaginal toxicity. These Nakagami parameters are derived from the statistics of ultrasound backscattered signals to capture the physical properties (e.g., arrangement and distribution) of the biological tissues. In this paper, we propose to expand this Nakagami imaging concept from 2D to 3D to fully characterize radiation-induced changes to the vaginal wall within the radiation treatment field. A pilot study with 5 post-radiotherapy GYN patients was conducted using a clinical ultrasound scanner (6 MHz) with a mechanical stepper. A serial of 2D ultrasound images, with radio-frequency (RF) signals, were acquired at 1 mm step size. The 2D Nakagami shape and PDF parameters were calculated from the RF signal envelope with a sliding window, and then 3D Nakagami parameter images were generated from the parallel 2D images. This imaging method may be useful as we try to monitor radiation-induced vaginal injury, and address vaginal toxicities and sexual dysfunction in women after radiotherapy for GYN malignancies.

A study to evaluate the cause of bone demineralization in gynecological cancer survivors.

An association between treatment for gynecological cancers and risk of osteoporosis has never been formally evaluated. Women treated for these cancers are now living longer than ever before, and prevention of treatment-induced morbidities is important. We aimed to distinguish, in gynecological cancer survivors, whether cancer therapy has additional detrimental effects on bone health above those attributable to hormone withdrawal. We performed a retrospective cross-sectional analysis of dual energy x-ray absorptiometry (DEXA) scan results from 105 women; 64 had undergone bilateral salpingo-oophorectomy (BSO) followed by chemotherapy or radiotherapy for gynecological malignancies, and 41 age-matched women had undergone BSO for benign etiologies. All were premenopausal prior to surgery. The median age at DEXA scan for the cancer group was 42 years, and 66% had received hormonal replacement therapy (HRT) following their cancer treatment. For the benign group, the median age was 40 years, and 87% had received HRT. Thirty-nine percent of cancer survivors had abnormal DEXA scan results compared to 15% of the control group, with the majority demonstrating osteopenia. The mean lumbar spine and femoral neck bone mineral densities (BMDs) were significantly lower in cancer patients. A history of gynecological cancer treatment was associated with significantly lower BMD in a multivariate logistic regression. Women treated for gynecological malignancies with surgery and adjuvant chemotherapy have significantly lower BMDs than age-matched women who have undergone oophorectomy for noncancer indications. Prospective evaluation of BMD in gynecological cancer patients is recommended to facilitate interventions that will reduce the risk of subsequent fragility fractures.

Noninvasive evaluation of vaginal fibrosis following radiotherapy for gynecologic malignancies: A feasibility study with ultrasound B-mode and Nakagami parameter imaging

This study's purpose is to develop a quantitative ultrasound technology to evaluate radiation-induced vaginal fibrosis. Radiation therapy (RT) is an important treatment modality for most gynecologic (GYN) malignancies. However, vaginal fibrosis is a common chronic side-effect, affecting 80% of women post vaginal or pelvic RT. Vaginal fibrosis leads to pain, sexual dysfunction, and poor quality of life. The authors propose a novel ultrasound approach that combines conventional B-mode imaging with Nakagami parameter imaging to quantitatively evaluate post-RT vaginal injury. From the B-mode image, vaginal wall thickness and echo intensity were calculated to capture the anatomy and echogenicity of the vaginal wall. From Nakagami imaging, two statistical parameters, Nakagami probability density function (PDF) and Nakagami shape, were computed to measure the concentration and arrangement of vaginal tissue microstructures. This novel ultrasound imaging concept was investigated in a pilot study of 12 patients, who were previously diagnosed and treated for endometrial cancer. The 12 participants were stratified into two groups: (1) the control group consisted of 6 patients who received surgery (hysterectomy) alone and (2) the post-RT group consisted of 6 patients who received surgery plus radiotherapy, with a follow-up time of 12-38 months. Each participant underwent one transvaginal ultrasound study (6 MHz). Three transverse images of the anterior vaginal wall were acquired in a 2 cm step from the apex (vaginal cuff) to the introitus (vagina opening). The vaginal wall thickness, echo intensity, Nakagami PDF, and Nakagami parameter were calculated to evaluate radiation-induced vaginal fibrosis. Both B-mode and Nakagami methods showed significant differences in parameters between the post-RT and nonirradiated vaginal walls. Compared with the control group, the vaginal wall thickness of the post-RT group increased by 153.2% (p = 0.002), the echo intensity increased by 11.6% (p = 0.017), the Nakagami PDF increased by 72.3% (p < 0.001), and the Nakagami shape valued increased by 33.0% (p = 0.028). Vaginal fibrosis appears to be associated with a thickened vaginal wall, higher echogenicity, as well as increased Nakagami PDF and shape parameters. This pilot study shows the authors' quantitative ultrasound approach combining B-mode and Nakagami imaging is a promising imaging method to evaluate vaginal fibrosis. This imaging method may be useful as physicians try to address vaginal toxicities and sexual dysfunction in women after radiotherapy for GYN malignancies.

Stereotactic Body Radiation Therapy for Gynecologic Malignancies

In this study, we present our experience with robotic radiosurgical SBRT for patients with primary gynecologic malignancies who have experienced either local, regional, or distant metastases after primary treatment and for those patients where SBRT was used as a boost if brachytherapy was not possible.

WE‐C‐BRA‐10: Ultrasound Nakagami Imaging for Noninvasive Evaluation of Vaginal Fibrosis Following Radiotherapy for Gynecologic Malignancies

Purpose: Radiation therapy is an important treatment modality for most gynecologic (GYN) malignancies. However, radiation‐induced vaginal fibrosis is a debilitating side‐effect, affecting 80% of women post pelvic or vaginal radiotherapy. Vaginal fibrosis leads to pain, sexual dysfunction, and poor quality of life. This study's purpose is to develop an ultrasonic tissue characterization technique based on Nakagami parameter imaging to evaluate vaginal fibrosis. Methods: We investigated the Nakagami imaging concept in a pilot study of 10 patients. All patients were previously diagnosed with endometrial cancer. Four patients who received surgery alone served as the control group. Six patients received surgery plus radiotherapy, and the follow‐up time ranged from 12 to 38 months after radiotherapy. Each participant underwent one transvaginal ultrasound study with a 7.5 MHz biplane probe. Three transverse images of the anterior vaginal wall were acquired in a 2 cm step‐wise progression from the apex (vaginal cuff) to the introitus (vagina opening). Vaginal wall thickness, Nakagami probability density function (PDF), and Nakagami parameter were calculated to evaluate radiation‐induced vaginal injury. Results: Significant differences in vaginal wall thickness and Nakagami PDF were observed between the post‐irradiation and non‐irradiated vaginal walls. The average vaginal wall thicknesses were 1.99±0.54 mm for the control group and 4.81±1.55 mm for the post‐irradiation group (p&lt;0.01). The average Nakagami PDF values were 2.05±0.13E‐3 for the control and 3.54±0.40E‐3 for the post‐irradiation group (p&lt;0.001). The average Nakagami parameter values were 0.92±0.31 for the control group and 1.31±0.12 for the post‐ irradiation group (p=0.15). Vaginal fibrosis appears to be associated with a thickened vaginal wall and increased Nakagami parameter. Conclusions: In this study, we demonstrate the feasibility of using Nakagami imaging to evaluate vaginal fibrosis. Quantitative ultrasound provides a noninvasive, objective means of assessing radiation‐induced vaginal injury. This imaging method may be useful as we try to address vaginal toxicities and sexual dysfunction in women after radiotherapy for GYN malignancies.